Neutrophil Elastase Inhibitor Increases Flap Survival in Experimental Degloving Injuries

Area of Science:

• Orthopedic Surgery
• Trauma Management
• Vascular Surgery

Background:

• Degloving hand injuries present significant management challenges due to extensive tissue damage.
• Traditional treatment involves flap resuturing with uncertain outcomes regarding flap viability.
• Ischemia-reperfusion injury is a critical factor in the success of flap survival.

Purpose of the Study:

• To evaluate Sivelestat's efficacy in enhancing avulsed flap survival in a rat degloving model.
• To compare Sivelestat's effects on ischemia-reperfusion injury with Pentoxifylline.
• To investigate the anti-inflammatory and anti-apoptotic properties of Sivelestat in this context.

Main Methods:

• Quantification of total flap area, necrotic area, and necrosis ratio.
• Assessment of angiogenesis using CD31 and anti-PECAM staining.
• Evaluation of apoptosis via TUNEL assay.

Main Results:

• Sivelestat (10 mg/kg/hour) demonstrated superior inhibition of ischemia-reperfusion injury compared to Pentoxifylline.
• Sivelestat showed more pronounced anti-inflammatory effects than Pentoxifylline's hemorheological actions.
• Evidence of enhanced flap survival and reduced apoptosis in Sivelestat-treated groups.

Conclusions:

• Sivelestat's anti-inflammatory properties are beneficial in mitigating early degloving injury complications like inflammation, sepsis, and edema.
• Sivelestat offers a more effective therapeutic approach than Pentoxifylline for managing ischemia-reperfusion injury in degloving scenarios.
• The findings support Sivelestat as a promising agent for improving outcomes in degloving injuries.